Skip to Content

No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

Dr. Jeff Sharman presents compelling data from multiple clinical trials, revealing the safety of acalabrutinib in treating blood disorders. The research, encompassing around 4,000 patient-years of acalabrutinib treatment, demonstrates no significant association with ventricular arrhythmias, a concern in similar therapies.

Jeff P. Sharman

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top